China Biotech

What China Biotech does

China Biotech (中国生物技术股份有限公司, dba CNBG / China National Biotech) is a Beijing-headquartered, state-owned biopharmaceutical conglomerate founded in 1919 and operating as a core member enterprise of Sinopharm Group (中国医药集团有限公司). It is China's oldest institution dedicated to infectious disease bacteriology research and biological product manufacturing, and the country's largest human vaccine producer — ranked fifth globally — supplying approximately 80% of China's national immunization program across all 15 targeted diseases and producing 50 vaccine varieties annually.

The company operates an integrated biologics platform organized around six business segments: human vaccines, blood products (5 manufacturing facilities, 14 product varieties, 2,000+ tons of annual plasma throughput), biological therapeutics (including monoclonal antibodies F61, 2B11, DXP-604 and a COVID-19 specific immunoglobulin), medical diagnostics (notably the first Chinese COVID-19 nucleic acid kit to receive both national and EU certification plus WHO Emergency Use Listing), medical aesthetics (China's only government-certified botulinum toxin producer), and animal health (60+ veterinary biological products with 100+ billion doses annual capacity). R&D activity includes 196 ongoing projects and an innovation-oriented product portfolio share of 42%. Manufacturing is carried out across 22 production bases and 14 subsidiaries under a quality system compliant with GMP, EU GMP, ISO 9001, and ICH Q10.

Commercially, China Biotech runs a hybrid go-to-market: a dominant, recurring-revenue government procurement channel feeding the national immunization program at approximately 80% market share, complemented by direct institutional sales of commercial vaccines, blood products, diagnostics, and aesthetics products to hospitals and clinics nationwide. The firm is a wholly-owned subsidiary of Sinopharm Group, has no public listing, and discloses no revenue figures publicly. Customer concentration is structurally tied to the Chinese central government for immunization volume, with secondary demand from domestic medical institutions and emerging international licensing channels.

Name

China Biotech

Legal name

中国生物技术股份有限公司

Website

https://cnbg.com.cn

Company type

Private

Founded year

1919

Operating status

Operating

Headcount range

51–100 employees

Short description

China Biotech (CNBG) is a state-owned Chinese biopharmaceutical conglomerate and the country's largest vaccine producer, supplying ~80% of the national immunization program and producing 50 vaccine types, blood products, diagnostics, aesthetics, and animal health biologics under Sinopharm Group.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC)

akta.pro secondary industries

Vaccine Manufacturing & Contract Services (Veterinary Vaccine CDMO) (HLAMAKAI), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Human vaccines
• Blood products
• Biotherapeutics
• Medical diagnostics
• Animal vaccines

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices7 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

1. National Immunization Program Vaccines: Government-procured vaccines for national immunization program covering 15 diseases, with approximately 80% market share of China's immunization program vaccine supply
2. Commercial Vaccines: Non-essential vaccines sold commercially to individuals and medical institutions, producing 50 types of vaccines annually
3. Blood Products: Blood products including human albumin, immunoglobulin, and clotting factors distributed to hospitals and clinics nationwide
4. Medical Diagnostics: Diagnostic reagents including COVID-19 nucleic acid tests, antigen tests, and antibody tests sold to medical institutions
5. Medical Aesthetics: Botulinum toxin products for medical aesthetics applications
6. Animal Healthcare Products: Veterinary biologics including vaccines for pigs, poultry, cattle, sheep, pets, and diagnostic products with annual capacity exceeding 10 billion doses

Pricing tiers

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Core offering

China Biotech is a state-owned biopharmaceutical manufacturer engaged in the research, production, and sale of human vaccines, blood products, therapeutic antibodies, medical diagnostics, medical aesthetics products (botulinum toxin), and animal health biologics. The company operates six major business segments across 14 subsidiaries and 22 production bases, supplying vaccines covering all 15 diseases in China's national immunization program and producing 50 vaccine varieties annually.

Product overview

China Biotech (中国生物技术股份有限公司/CNBG) operates as a comprehensive biotech conglomerate with six major business segments: Human Vaccines (largest in China, 5th globally, producing 50 vaccine types with 80% domestic market share), Blood Products (5 manufacturers, 14 varieties across 3 categories), Biological Treatment (antibody drugs and molecular diagnostics including COVID treatments F61, 2B11, DXP-604), Medical Diagnostics (COVID nucleic acid tests, rapid tests), Medical Aesthetics (botulinum toxin), and Animal Health (60+ veterinary products). The company is a member of Sinopharm Group and was founded in 1919, making it China's oldest biotech institution.

Differentiator

Problem solved

Functional benefit

Products and services

• Human Vaccines Comprehensive human vaccine portfolio for disease prevention, with 80% market share of China's national immunization program vaccine supply and ranked 5th globally among vaccine manufacturers.
• Blood Products Blood products including human albumin, immunoglobulin, and clotting factors, with 14 varieties across 3 categories, 72 production approvals, and annual plasma processing capacity exceeding 2,000 tons.
• Biological Treatment Products Therapeutic antibody drug portfolio including COVID-19 specific immunoglobulin and monoclonal antibodies (F61, 2B11, DXP-604) for infectious disease treatment.
• Medical Diagnostics Diagnostic reagents including COVID-19 nucleic acid tests, rapid 30-minute antigen tests, and antibody tests for medical institutions and laboratories.
• Medical Aesthetics (Botulinum Toxin) Government-certified botulinum toxin products for medical aesthetics and clinical applications, supplied as the sole authorized domestic producer in China.
• Animal Health Products Six categories of over 60 veterinary biological products including vaccines for pigs, poultry, cattle, sheep, pets, plus diagnostic products and therapeutic agents, with annual capacity exceeding 10 billion doses.
• COVID-19 Inactivated Vaccines COVID-19 inactivated vaccines that received conditional market approval for pandemic response and prevention.
• Influenza Vaccine Seasonal influenza vaccine as part of the company's commercial vaccine portfolio.

Quantifiable outcome

• 80% market share in China's national immunization vaccine supply
• +4 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature6 records

Partnerships

One partnership is on record.

• Bo Rui Ce Bioscience (博瑞策生物)strategicStrategic or Co-development Partner · 1 July 2026Strategic cooperation between China Biological Products Research Institute and Bo Rui Ce Bioscience for biosafety detection and verification services

Scale indicators16 records

Broad incumbents

• Sanofi Pasteur: The vaccine division of Sanofi, one of the world's largest vaccine manufacturers with deep immunization-portfolio overlap and a similar focus on routine pediatric vaccines and emerging-market supply.
• Grifols: Global leader in plasma-derived blood products (albumin, immunoglobulins, clotting factors), directly comparable to CNBG's blood-products segment that processes 2,000+ tons of plasma annually across five manufacturing subsidiaries.
• Pfizer: Global biopharmaceutical leader with one of the world's largest vaccine franchises (including COVID-19 Comirnaty); competes for international tenders and pandemic-response contracts while operating at materially larger scale.
• GlaxoSmithKline: Global vaccine major with a broad pediatric and adult immunization portfolio competing for the same WHO and government immunization contracts that drive CNBG's international growth ambitions.
• CSL Limited: Australia-based global leader in both human vaccines (CSL Seqirus) and blood plasma products (CSL Behring), with directly overlapping business segments and similar end-markets, although geographically diversified outside China.

Direct peers

• Walvax Biotechnology: Chinese vaccine manufacturer producing routine immunization and innovative vaccines across multiple pathogens, with scale and product breadth directly comparable to CNBG's human vaccine portfolio.
• Sinovac Biotech: Another major Chinese vaccine manufacturer with a comparable focus on infectious-disease vaccines (including COVID-19 inactivated vaccines) and pediatric immunization products, competing directly with CNBG for global and domestic market share.
• Bharat Biotech: Indian vaccine manufacturer with a comparable scale and breadth of human vaccines including COVID-19 candidates; competes with CNBG in WHO pre-qualification, low-cost pediatric immunization, and emerging-market supply.
• Hualan Biological Engineering: Chinese biopharmaceutical company with overlapping human vaccine and blood-plasma product businesses, operating similar GMP-certified manufacturing and competing for the same NIP and commercial hospital channel.

Regional players

• Shanghai Pharmaceuticals Holding: Major Chinese state-affiliated pharmaceutical conglomerate operating in overlapping hospital and institutional channels for blood products, diagnostics, and biologics, although with a broader pharmaceutical focus rather than CNBG's vaccine specialization.

Market position

Strengths5 records

Weaknesses5 records

Key risks5 records

Key highlights7 records

Customer concentration

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about China Biotech